ImmunityBio is a clinical-stage biotechnology company that is redefining the landscape of immunotherapy. By focusing on the development of next-generation therapies for cancer and infectious diseases, the company aims to move beyond symptomatic treatment to provide long-lasting, curative solutions. Their work is built on the foundation of harnessing the body's natural defense systems.
As a publicly traded organization (NASDAQ: IBRX), ImmunityBio combines the agility of a biotech innovator with the resources of a commercial-stage firm. Employees are empowered to work on groundbreaking science in a collaborative, mission-driven environment that values both technical excellence and professional growth.